RegulationFast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China), Special Review Project (China)

Structure/Sequence

Molecular FormulaC23H30Cl2N8O4

InChIKeySTGQPVQAAFJJFX-UHFFFAOYSA-N

CAS Registry1402152-13-9

Clinical Trials associated with Copanlisib dihydrochloride

NCT05687721

/ WithdrawnPhase 1/2IIT

A Phase II Trial With Copanlisib Plus Avelumab as a Maintenance Therapy for Metastatic Bladder Cancer After Platinum-based Chemotherapy

Patients with metastatic bladder cancer are usually treated with chemotherapy. If their cancers do not progress after chemotherapy, they can be enrolled into this study and receive a standard-of-care immunotherapy medication named avelumab plus a study drug named copanlisib.

Start Date02 Jun 2025

Sponsor / Collaborator

VA Office of Research and Development

[+1]

NCT06218667

/ WithdrawnPhase 1/2IIT

CHARIOT: a Phase 1b/2 Study of Androgen Deprivation Therapy and Copanlisib in High-Risk Localized Prostate Cancer Patients Prior to Radical Prostatectomy

The researchers are doing this study to find out whether copanlisib in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side effects for people who have localized high-risk prostate cancer.

Start Date11 Jan 2024

Sponsor / Collaborator

Memorial Sloan Kettering Cancer Center

NCT05082025

/ TerminatedPhase 2IIT

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

The purpose of this study is to evaluate the efficacy and safety of copanlisib in combination with fulvestrant in advanced hormone receptor-positive (HR+) solid tumors harboring alterations that activate the Phosphatidylinositol-3 kinase (PI3K) pathway.

Start Date27 Sep 2022

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

100 Clinical Results associated with Copanlisib dihydrochloride

100 Translational Medicine associated with Copanlisib dihydrochloride

100 Patents (Medical) associated with Copanlisib dihydrochloride

299

Literatures (Medical) associated with Copanlisib dihydrochloride

01 Sep 2026·Translational Oncology

Combined inhibition of CDK4/6 and PI3K pathways exhibit highly synergistic activity and translational potential in Ewing sarcoma

Article

Author: Crompton, Brian D ; Finstuen-Magro, Sarah ; Shulman, David S ; McDannell, Brigit ; Blandin, Anne-Florence ; Meyer, Stephanie ; Klega, Kelly ; Chakraborty, Advaita ; Shen, Min ; Zhang, Ya-Qin ; Hall, Matthew D ; DuBois, Steven G ; Aguilar-Quintero, Alejandra ; Gloege, Helen F ; Tanhaemami, Mohammad ; Heaslip, Caleb O ; De Los Santos, Maria Ana Isabel C ; Chadha, Madhav

Ewing sarcoma is a highly aggressive solid malignancy affecting children and young adults. Ewing sarcoma is driven primarily by EWSR1::FLI1, a fusion oncoprotein that has been notoriously difficult to target with traditional pharmacologic agents. There are numerous examples of promising preclinical combinations of small molecules that are never tested in pediatric clinical trials because agents fail to reach the market due to limited efficacy for common adult cancers. Moreover, the effectiveness of single-agent therapies for cancer treatment is often limited. To address these limitations, we selected 28 compounds that were FDA approved at the time of the study or in late stages of clinical development and known to regulate important pathways in Ewing sarcoma. We performed a drug screen in Ewing sarcoma cell lines with 180 combinations of tyrosine kinase inhibitors, cell cycle inhibitors, and conventional chemotherapy. The results of the screen revealed that a PI3K inhibitor, copanlisib, combined with a CDK4/6 inhibitor, ribociclib, exhibited strong synergistic anti-Ewing sarcoma activity. Using proteomic methods such as a reverse-phase protein array and western immunoblotting, we demonstrated that this combination induced a downregulation of the PI3K/AKT pathway as well as proteins involved in cell cycle regulation. We further confirmed these in vitro data using bulk RNA-sequencing. To evaluate the phenotypic effect of the PI3K/CDK4/6 inhibition in Ewing sarcoma lines, we performed apoptosis and cell cycle analyses using flow cytometry and demonstrated that ribociclib primarily induced a G0/G1 arrest with minimal effect on Ewing cell viability but significantly enhanced the apoptotic effect of copanlisib treatment. In two xenograft models of Ewing sarcoma, we demonstrated that the combination significantly prolonged survival compared to treatment with either vehicle or single-agent therapy alone. Our findings identify a new candidate therapy combination for Ewing sarcoma and provide a resource of additional potential synergistic combinations for future validation.

01 Aug 2026·Clinical Lymphoma Myeloma & Leukemia

A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Article

Author: Shipp, Margaret ; Herrera, Alex ; Crombie, Jennifer L ; Parry, Erin ; Bartlett, Nancy ; LaCasce, Ann ; Davids, Matthew S ; Jacobsen, Eric ; Jacobson, Caron A ; Fisher, David ; Odejide, Oreofe ; Redd, Robert ; Patterson, Victoria ; Kim, Austin I ; Carey, Celeste ; Balasubramanian, Sobana ; Shouse, Geoffrey ; Merryman, Reid W ; Armand, Philippe

BACKGROUND:

Preclinical data support the combination of venetoclax and copanlisib in specific genomic subgroups of diffuse large B-cell lymphoma (DLBCL).

PATIENTS AND METHODS:

In this investigator-initiated, phase I, multicenter trial we aimed to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of copanlisib and venetoclax in patients with relapsed/refractory (R/R) DLBCL. Key eligibility criteria included relapse after or noncandidate for autologous stem cell transplantation or chimeric antigen receptor T-cell therapy and adequate hematologic and organ function. Key exclusion criteria were poorly controlled hypertension or diabetes.

RESULTS:

A total of 12 patients enrolled using a 3 + 3 design. The median age was 62 years (range 24-87 years) and 83% were male. The median number of prior treatments was 6 (range 1-11) and 10 patients had received prior CAR T-cell therapy. There were no dose limiting toxicities (DLT)s in dose level (DL)+2. Half of patients (2/4) in DL+3 were not able to escalate to 800 mg of venetoclax due to neutropenia and nonadherence. Key hematologic toxicities included neutropenia (50%, all grade (G) 3/4) and thrombocytopenia (42%, 17% ≥ G3), and the most common nonhematologic toxicities included nausea (33%, 8% ≥ G3), diarrhea (25%, all G1/2), elevated alkaline phosphatase (25%, 8% ≥ G3), fatigue (25%, all G1/2), and headache (25%, all G1/2). One patient had a complete response lasting 3 months. The median overall survival and progression-free survival were 4.1 and 1.6 months, respectively.

CONCLUSION:

Although the combination was tolerable, efficacy was poor in this unselected, heavily pretreated population.

03 Jul 2026·Expert Opinion On Drug Safety

Infectious complications associated with immune and targeted anti-cancer therapies: a retrospective study of the FDA adverse events reporting system (FAERS)

Article

Author: Alsowaida, Yazed S. ; Alsolami, Ahmed ; Abraham, Ivo ; Almangour, Thamer A.

BACKGROUND:

Immune and targeted anti-cancer therapies are associated with an increased risk of infectious complications. The objectives of the present study were to evaluate the infectious complications associated with immune and targeted anti-cancer drugs.

RESEARCH DESIGN AND METHODS:

This was a retrospective study for immune and targeted anti-cancer drugs submitted to the FDA Adverse Event Reporting System (FAERS) from 1996 to 20 March 2024. The primary outcome was the rate of infectious disease events, and the secondary outcomes were the incidence of febrile neutropenia (FN), all-cause mortality, and the top 10 infections in each class.

RESULTS:

Our study included 14 drug classes comprising 44 drugs. The incidence of infectious complications was 14.31% (110,671/773,130). The highest incidence rate was reported with IL-6 inhibitors (30.89%), the highest incidence of FN was reported with Histone deacetylase inhibitors (8.43%), and the highest all-cause mortality was reported with BCR-ABL tyrosine kinase inhibitors (17.17%).

CONCLUSION:

Immune and targeted anti-cancer therapies vary in the incidence of infectious complications. Pirtobrutinib, copanlisib, sirolimus, vorinostat, and tocilizumab were associated with high infectious complications (>30%) that warrant emphasis in the clinical guidelines. Thus, clinicians should vigilantly monitor patients undergoing immune and targeted therapies for infectious complications and use antimicrobial prophylaxes when indicated.

News (Medical) associated with Copanlisib dihydrochloride

24 Aug 2026

·www.prnewswire.com

BRC Therapeutics Appoints Biopharma Veteran Chandra Ramanathan as Executive Vice President of Commercialization and Strategy

Seasoned Executive Brings Track Record of Drug Launches, External Innovation, and Portfolio Growth at Bristol Myers Squibb, Wyeth, Bayer, and Danaher to BRC's Next Phase of Growth MONTEREY, Calif., Aug. 24, 2026 /PRNewswire/ -- BRC Therapeutics (BRC), a clinical-stage pharmaceutical company developing multimodal cannabinoid therapeutics for neurological and inflammatory conditions, today announced the appointment of Chandra Ramanathan, Ph.D., M.B.A., as Executive Vice President of Commercialization and Strategy. Ramanathan brings more than 30 years of biopharmaceutical leadership spanning drug development, global product launches, commercialization, and external innovation to BRC as the company advances its pipeline and prepares for its next phase of growth. Ramanathan joins BRC from Danaher Corporation, where he served as Vice President and Global Head of Innovation Hubs and Head of External Innovation, Life Sciences Innovation Group (LSIG) building a funnel of product-oriented partnerships across genomic medicine, diagnostics, LSIG, and biomanufacturing. Prior to Danaher, he spent more than 12 years at Bayer, most recently as Global Head of Pharma R&D Open Innovation, where he chaired the Open Innovation Committee overseeing an annual investment budget of more than $90 million across more than 50 academic and biotech partnerships. While leading Bayer's East Coast Innovation Center in Cambridge, MA, Ramanathan built major partnerships with the Broad Institute, MassGeneral Brigham, and Johns Hopkins University. Earlier in his career, Ramanathan led global launch teams behind two approved therapies (Bosulif®, Aliqopa®) and contributed to the launches of Orencia®, and Sprycel® across roles at Wyeth (now Pfizer), Bristol Myers Squibb, and Bayer. As the Head of oncology strategic marketing, he grew Bayer's oncology clinical portfolio from two assets to fifteen over five years. His experience spans the full spectrum of drug development and commercialization: external innovation, product development, companion diagnostics strategy, portfolio and launch planning, and building cross-functional global teams across the U.S., Europe, and Asia. "Chandra has spent his career doing precisely what BRC needs next: progressing promising science into the next phase of clinical development and ultimately into approved medicines that reach patients, based on proven growth strategies and commercial infrastructure to get there," said George Hodgin, Founder and CEO of BRC Therapeutics. "He has led launches at some of the most respected companies in our industry, built innovation engines from the ground up, and has a rare ability to move fluidly between science, innovation strategy, and commercial strategy. As we advance our pipeline in CRPS, AIIA, RLS and additional indications and prepare for our next phase of growth, Chandra's judgment, expertise and experience will be invaluable." "BRC is pursuing something genuinely novel: FDA-regulated cannabinoid medicines for patients with too few good options. The company's foundation is innovative science, a strong intellectual property estate, unique and evolving regulatory approach, and an unwavering drive to make a difference for patients," said Chandra Ramanathan. "I've spent my entire career helping companies bridge early science and commercial reality, and I see that same opportunity here. I'm excited to work alongside George and the BRC team as the company moves toward pivotal trials, new opportunities, and ultimately helping patients." Ramanathan currently serves as Chairperson of the Board of Directors of Nucleate, a nonprofit developing the next generation of biotech entrepreneurs, and holds board and advisory roles with the McLean Hospital, the Johns Hopkins University Innovation, Development & Entrepreneurial Advisory Board and Harvard Business School Blavatnik Fellowship Council. He was also a board member with MassBIO and Chair of the Innovation Committee where he recently finished his 9-year term. He is also an Adjunct Assistant Professor at Tufts University School of Medicine. Ramanathan holds an M.B.A. from Columbia Business School and a Ph.D. in Genomics and Bioinformatics from the University of Georgia. BRC Therapeutics (BRC) is a pharmaceutical company focused on developing innovative therapeutics to deliver relief from pain and other symptoms in chronic conditions. BRC's medicines are multimodal and contain cannabinoids at defined ratios. BRC has developed a pipeline of investigational prescription medicines addressing neurological and inflammatory conditions. Investigational products are currently being tested in clinical trials for Complex Regional Pain Syndrome (CRPS), Restless Legs Syndrome (RLS), and Aromatase Inhibitor-Induced Arthralgia (AIIA) and an additional confidential indication. BRC is registered with the Drug Enforcement Administration and is based in Monterey, CA. To learn more about BRC, visit . Forward-Looking Statements This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks, uncertainties and assumptions, including without limitation statements about the development, use, benefits and effects of BRC Therapeutics' (BRC) therapeutic product candidates and related technology, future plans for BRC's business and growth, and expected plans with respect to clinical trials, including the number of patients enrolled and timing of patient enrollment. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "design," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements. The forward-looking statements made herein speak only as of the date of this press release and, unless otherwise required by law, BRC does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. SOURCE BRC Therapeutics 21% more press release views with Request a Demo

Executive Change

28 May 2025

·frederick.cancer.gov

ASCO oral presentation, posters to explore use of liquid biopsy in rare cancers

Results of two studies matching genomic profiling in patient biopsies and circulating tumor DNA (ctDNA) in plasma of rare cancers will be presented by Frederick National Laboratory for Cancer Research (FNL) scientists at the American Society for Clinical Oncology Annual Meeting, May 30 to June 3 at McCormick Place in Chicago. Cancer types such as small cell lung, adenocarcinoma of the esophagus, adenocarcinoma of the pancreas and salivary gland cancer are considered rare, or less-common tumors. While there is growing data validating liquid biopsies in the more common breast, colon, prostate and non-small cell lung cancers, there are fewer studies on the less-common tumors. Sixty percent of patients screened for an arm of the National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) precision medicine trial had less-common tumors. As part of the screening, patients provided tumor biopsy tissue for genomic profiling evaluation. They also provided plasma samples. Scientists from FNL’s Molecular Characterization Laboratory (MoCha) tested the ctDNA of 2,194 patients with less-common tumors and compared each genomic profile to that of the corresponding patient’s tumor biopsy results. In nearly 86% of patients, scientists identified the same mutations in the tumor as in the ctDNA in the blood. “Comprehensive genomic profiling of matched ctDNA and tissue from patients with less-common cancers enrolled in but not eligible for a treatment arm of the NCI-MATCH trial.” Presenter: Biswajit Das “Classification of histology based on ctDNA fragmentomic analysis in patients with uncommon cancers screened for NCI-MATCH." Presenter: Chris Karlovich “Digital spatial profiling of advanced solid tumors and lymphomas from a Phase 1 trial of copanlisib and nivolumab.” Presenter: Biswajit Das Biswajit Das, Ph.D., MoCha associate director, will present this study in an oral abstract session on Friday, May 30 at 4:45 CT in Hall D1 of the convention center. In another study, scientists evaluated the ctDNA to determine fragmentation patterns, which are unique to each tumor type and can help more precisely identify the cancer. The fragment-based model accurately identified the cancer type in nearly 100% of samples that were definitively diagnosed in pathology. About 5% of the time, patient samples are determined “not otherwise specified (NOS)” in pathology reports. The tumor’s origin is unknown, or the sub-type of a cancer cannot be determined. Using the fragmentation data, Peter Wu and colleagues accurately identified sub-types of pancreatic and ovarian cancer, indicating ctDNA could be used as a tool to more precisely classify tumor types. MoCha Director Chris Karlovich, Ph.D., will present the study in the Poster Session on Monday, June 2 from 1:30 to 4:30 CT. Another study by MoCha scientists showed that the digital spatial profiling (DSP) technique can be used to analyze small sections of a tumor biopsy, providing greater insight into the tumor and the tumor microenvironment. This study, led by Sayak Ghatak, will be presented in the Poster Session on Monday, June 2 from 1:30 to 4:30 CT. Mary Ellen Hackett Manager, Communications Office 301-401-8670

ASCOPhase 1Clinical Result

09 Aug 2024

·www.fda.gov

FDA grants accelerated approval to copanlisib for relapsed follicular lymphoma

On September 14, 2017, the U.S. Food and Drug Administration granted accelerated approval to copanlisib (ALIQOPA, Bayer HealthCare Pharmaceuticals Inc.) for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. Approval was based on efficacy results in 104 patients with relapsed follicular lymphoma enrolled in an open-label, single-arm, multicenter, phase 2 trial. Patients received 0.8 mg/kg or 60 mg of copanlisib by intravenous infusion on days 1, 8, and 15 of a 28-day treatment cycle. The objective response rate was 58.7% (95% CI: 48.6%-68.2%) with an estimated median response duration of 12.2 months (range, 0+ to 22.6 months). The complete response rate was 14.4% and partial response rate was 44.2%. The safety population included 168 patients with follicular lymphoma and other hematologic malignancies treated with the recommended copanlisib dosing regimen. Common adverse reactions in greater than 20% of patients include hyperglycemia, diarrhea, fatigue, hypertension, leukopenia, neutropenia, nausea, lower respiratory tract infections, and thrombocytopenia. The most common grade 3-4 adverse reactions include hyperglycemia, leukopenia, hypertension, neutropenia, and lower respiratory tract infections. Serious non-infectious pneumonitis occurred in 6% of patients. The recommended copanlisib dose is 60 mg administered as a 1-hour intravenous infusion on days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (three weeks on and one week off). Full dosing information is available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf FDA previously granted orphan drug and fast track designation for copanlisib. As a condition of accelerated approval, a randomized controlled trial will be required to verify the clinical benefit of copanlisib. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics, available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System by completing a form online at http://www.fda.gov/medwatch/report.htm, by faxing (1-800-FDA-0178) or mailing the postage-paid address form provided online, or by telephone (1-800-FDA-1088). Follow the Oncology Center of Excellence on Twitter@FDAOncology. Check out recent approvals at the OCE’s new podcast, Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.), available at www.fda.gov/DISCO. Content current as of: 09/14/2017 09/14/2017 Resources for Information | Approved Drugs Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) Short Description Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) Short Description

Accelerated ApprovalClinical ResultFast TrackDrug ApprovalOrphan Drug

100 Deals associated with Copanlisib dihydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D10797 D10867	Copanlisib dihydrochloride	L01XX61	DB12483

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Follicular Lymphoma	United States	Bayer HealthCare Pharmaceuticals, Inc.	14 Sep 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Indolent B-Cell Non-Hodgkin Lymphoma	NDA/BLA	Canada	Bayer, Inc.	01 Dec 2021
Small Lymphocytic Lymphoma	NDA/BLA	Canada	Bayer, Inc.	01 Dec 2021
Waldenstrom Macroglobulinemia	NDA/BLA	Canada	Bayer, Inc.	01 Dec 2021
Marginal Zone B-Cell Lymphoma	NDA/BLA	European Union	Bayer AG	12 Jun 2021
Non-Hodgkin Lymphoma	NDA/BLA	China	Bayer AG	10 Mar 2021
Indolent Non-Hodgkin Lymphoma	Phase 3	United States	Bayer Pharma AG	06 Jan 2016
Indolent Non-Hodgkin Lymphoma	Phase 3	United States	Bayer Healthcare Co., Ltd.	06 Jan 2016
Indolent Non-Hodgkin Lymphoma	Phase 3	Argentina	Bayer Healthcare Co., Ltd.	06 Jan 2016
Indolent Non-Hodgkin Lymphoma	Phase 3	Argentina	Bayer Pharma AG	06 Jan 2016
Indolent Non-Hodgkin Lymphoma	Phase 3	Australia	Bayer Pharma AG	06 Jan 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03711058 (Pubmed \| Nat Commun)	Phase 1/2	Metastatic Microsatellite Stable Colorectal Carcinoma microsatellite stable \| PIK3CAwt \| PIK3CAmut	39	Copanlisib/nivolumab (PIK3CAwt)	nodnedhgdn(vokdavyhxr) = oodnwsklkn qglfglunzo (mfykyllthh ) View more	Negative	23 Jul 2026
				Copanlisib/nivolumab (PIK3CAmut)	nodnedhgdn(vokdavyhxr) = noaqcvmjnh qglfglunzo (mfykyllthh ) View more
NCT03789240 (CTgov)	Phase 2	Follicular Lymphoma	33	Copanlisib+Rituximab	egkwysjofn = trtmtquhks teexlucdaa (xykilncvxs, aikbkdcfhq - yyhwxqmhmb) View more	-	03 Mar 2026
NCT03842228 (COD, CTgov)	Phase 1	Metastatic Solid Tumor \| Advanced Malignant Solid Neoplasm \| Unresectable Solid Neoplasm	39	Copanlisib+Olaparib (Step 1 Dose Level 1)	tsnemacbpf = ensvplpgbr wyydxrloro (uthpzowavv, mxxucknjyf - mfejkzjpkw) View more	-	03 Aug 2025
				Copanlisib+Olaparib (Step 1 Dose Level 2)	tsnemacbpf = vthursbsnn wyydxrloro (uthpzowavv, kwvcnubwak - awzvhlxrjn) View more
NCT04345913 (CTgov)	Phase 1/2	Metastatic breast cancer \| Metastatic Triple-Negative Breast Carcinoma	24	Computed Tomography+Copanlisib Hydrochloride+Eribulin Mesylate (Phase I, DL1 (Eribulin, Copanlisib))	awtzmdoldu = hwtgdkppcj fbyzwuuoea (hnypguiqgy, dqcjtccczn - pvjpkiqkqb) View more	-	28 Jul 2025
				Computed Tomography+Eribulin Mesylate (Group I (Phase II, Eribulin))	mjokoblmzo(tarztrognw) = gtxjulxrjk kgczctrvnx (kgbbjktlhn, ruvvckrakk - wkmgwmgywv) View more
NCT05082025 (CTgov)	Phase 2	Ovarian Cancer \| Endometrial Carcinoma	7	Copanlisib+Fulvestrant	arbbcynqty = mbhwpiasif ctlspyzlvk (azowsqwetk, xvjvcmnhti - qaufvvxxrv) View more	-	11 Jul 2025
A PROSPECTIVE MULTICENTER PHASE 2 STUDY (EHA2025)	Phase 2	Bcl-2/IgH-rearrangement	102	Copanlisib plus Obinutuzumab	wrpumuyomw(bcvloirath) = rylardlxep eieduizogr (zgyvdplfsi, 93 - 100) View more	Positive	14 May 2025
NCT06400238 (CTgov)	Phase 2	Refractory Malignant Solid Neoplasm \| Advanced Malignant Solid Neoplasm \| Advanced Lymphoma ... View more	35	Computed Tomography+Copanlisib	emxsydnmdx = zhkztmrbsp cvenwitprj (nyjsxcbprk, owybawzcpu - rtlpzxlotc) View more	-	16 Apr 2025
NCT06360588 (CTgov)	Phase 2	Malignant Solid Neoplasm	22	Radiologic Examination+Copanlisib	nuiqsbnueo = ctlkodypxz vlgxyaqmgq (ziwbfwwbrg, szqzaosxqv - jvrenajhuu) View more	-	16 Apr 2025
NCT04750941 (CTgov)	Phase 2	Refractory Follicular Lymphoma \| Endometrial Carcinoma	1	Copanlisib+Ketogenic Diet (Follicular Lymphoma (FL))	gakknolkrl = xfymdnzeyg ixtptvzxgg (ngnzrmusia, lbmuiacvwa - imnnbqmitj) View more	-	04 Mar 2025
				Copanlisib+Ketogenic diet (Endometrial Cancer (EC))	lzqxatoeoo(fhfvgiqrqn) = ledotoqzzm vhlrlvbudk (oflqosjpbb, hoeqnavdiy - dqfcqvralo) View more
NCT04462471 (CTgov)	Phase 1	Thyroid Cancer, Follicular \| Papillary thyroid cancer \| Refractory Thyroid Gland Carcinoma	8	Copanlisib+Vemurafenib (Dose Level 1)	yhuchljpcs = blmenuduja aweomzrthg (nlqoighniq, vocefonxyx - cvkieaynit) View more	-	28 Feb 2025
				Copanlisib+Vemurafenib (Dose Level 2)	yhuchljpcs = lcbczjzhyc aweomzrthg (nlqoighniq, yhpidrbgeq - pvtbkdnrii) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis